Thermo Fisher Scientific’s clinical research arm, PPD, has entered into a Phase 3 trial design agreement with AIM ImmunoTech Inc. to develop Ampligen, a late‑stage pancreatic cancer therapy. The contract, announced on March 2 2026, will see PPD design the study protocol, statistical analysis plan, and operational framework for the upcoming Phase 3 trial.
While the financial terms of the agreement were not disclosed, the partnership signals a new recurring revenue stream for PPD and expands its oncology portfolio. PPD, which was acquired by Thermo Fisher in 2021 for $17.4 billion, has supported more than 700 oncology and hematology trials and is now positioned to capture additional oncology service contracts.
AIM ImmunoTech, a small biotech with limited revenue and significant net losses, is leveraging the partnership to advance Ampligen. The company’s Phase 2 DURIPANC trial in late‑stage pancreatic cancer has shown promising progression‑free and overall survival results, and the Phase 3 design will build on those findings.
Thermo Fisher’s Q4 2025 results—revenue of $12.21 billion (up 7 %) and adjusted EPS of $6.57 (up 8 %)—illustrate the strength of its core businesses. The company guided 2026 revenue to $46.3 billion–$47.2 billion and adjusted EPS to $24.22–$24.80, reflecting confidence in continued growth and margin maintenance.
Strategically, the deal reinforces Thermo Fisher’s one‑stop‑shop model for life‑science customers and positions PPD to capture more oncology service contracts. For AIM, partnering with a CRO of PPD’s scale provides the operational expertise needed to advance Ampligen toward regulatory approval and potential commercialization.
AIM CEO Thomas K. Equels said, “The ongoing Phase 2 DURIPANC clinical trial of Ampligen and AstraZeneca’s durvalumab in the treatment of late‑stage pancreatic cancer is producing promising results. Based on the success so far, we believe it is now time to start mapping out the next steps for AIM’s development of Ampligen as a therapy for pancreatic cancer.” Thermo Fisher CEO Marc Casper noted, “We delivered a strong year, capped off by an excellent fourth quarter. Our results reflect outstanding execution from the team, the strength of our proven growth strategy and excellent operational performance enabled by our PPI Business System.”
No immediate market reaction data are available for this specific announcement, but Thermo Fisher’s Q4 2025 earnings had a decline after cautious guidance, indicating that investors closely monitor forward guidance. The new Phase 3 design agreement is likely to be viewed positively as it expands PPD’s oncology service offering and provides AIM with a critical partnership to advance Ampligen.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.